DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Monday morning. The firm issued a hold rating on the stock.

Several other brokerages have also recently issued reports on DBVT. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st.

DBV Technologies Stock Down 2.8 %

DBVT opened at $0.68 on Monday. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.28. The business has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $0.96. The firm has a market cap of $65.62 million, a P/E ratio of -0.81 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. Sell-side analysts expect that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. raised its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.